Complement-mediated thrombotic microangiopathy secondary to sepsis-induced disseminated intravascular coagulation successfully treated with eculizumab: A case report

Secondary thrombotic microangiopathies (TMAs) are induced by several underlying conditions; most are resolved by treating background disease. Eculizumab is a human monoclonal antibody that blocks the final stage of the complement system and effectively treats atypical hemolytic uremic syndrome (aHUS...

Descripción completa

Detalles Bibliográficos
Autores principales: Abe, Tomohiro, Sasaki, Akira, Ueda, Taichiro, Miyakawa, Yoshitaka, Ochiai, Hidenobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
3900
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313012/
https://www.ncbi.nlm.nih.gov/pubmed/28178155
http://dx.doi.org/10.1097/MD.0000000000006056

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5313012/
https://www.ncbi.nlm.nih.gov/pubmed/28178155
http://dx.doi.org/10.1097/MD.0000000000006056

Ejemplares similares